Innovation, investment, and ideals intersected dramatically at the AI Action Summit—held 10–11 February at Paris’s Grand Palais. Co-chaired …
Innovation, investment, and ideals intersected dramatically at the AI Action Summit—held 10–11 February at Paris’s Grand Palais. Co-chaired …
Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Despite a cautious capital environment, North American biotech companies secured nearly $2 billion in funding in January 2025, with …
A new survey finds that over 80% of healthcare professionals notice sex-related differences in disease progression and treatment …
Neumora Therapeutics sees its share value collapse as its lead antidepressant candidate, navacaprant, fails to outperform placebo in …
As traditional VC investment remains selective, firms like Abingworth and Vie Ventures are pioneering fresh approaches—launching billion-dollar trials …
Blending single-cell biology with generative AI, Cellarity launches its first-in-human trial for CLTY-101—an engineered cell therapy targeting tumor …
Landmark Series A round positions Australian biotech at the forefront of neurodegenerative disease innovation.
With a fresh $153 million in funding, Strand Therapeutics is pushing the boundaries of mRNA technology—this time, in …
AI-driven drug discovery is accelerating innovation and transforming biopharma R&D.
Already a subscriber? Log in